{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?sponsor=UCB+Pharma+SA",
    "query": {
      "sponsor": "UCB Pharma SA"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 9,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-10-02T05:48:06.315Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01728077",
      "title": "Evaluation of Long-term Safety, and Efficacy of Brivaracetam (BRV) Used as Adjunctive Treatment in Subjects With Epilepsy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Epilepsy"
      ],
      "interventions": [
        {
          "name": "Brivaracetam",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "UCB Pharma SA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 26,
      "start_date": "2012-10",
      "completion_date": "2016-08",
      "has_results": true,
      "last_update_posted_date": "2018-07-11",
      "last_synced_at": "2026-10-02T05:48:06.315Z",
      "location_count": 6,
      "location_summary": "Little Rock, Arkansas • Lexington, Kentucky • New York, New York + 3 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Akron",
          "state": "Ohio"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01728077"
    },
    {
      "nct_id": "NCT01653262",
      "title": "Effect of Brivaracetam (BRV) on Nonpsychotic Behavioral Side Effects in Subjects Treated Previously With Levetiracetam (LEV)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Epilepsy"
      ],
      "interventions": [
        {
          "name": "Brivaracetam",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "UCB Pharma SA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 29,
      "start_date": "2012-07",
      "completion_date": "2013-11",
      "has_results": true,
      "last_update_posted_date": "2018-07-11",
      "last_synced_at": "2026-10-02T05:48:06.315Z",
      "location_count": 6,
      "location_summary": "Little Rock, Arkansas • Lexington, Kentucky • New York, New York + 3 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Akron",
          "state": "Ohio"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01653262"
    },
    {
      "nct_id": "NCT00160524",
      "title": "A follow-on Safety Study of CDP870 in Subjects With Crohn's Disease (CD) Who Have Completed a 26-week Double Blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425]",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Crohn's Disease"
      ],
      "interventions": [
        {
          "name": "Certolizumab Pegol (CDP870)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "UCB Pharma SA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 596,
      "start_date": "2004-07",
      "completion_date": "2012-08",
      "has_results": true,
      "last_update_posted_date": "2018-08-01",
      "last_synced_at": "2026-10-02T05:48:06.315Z",
      "location_count": 47,
      "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Tucson, Arizona + 40 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00160524"
    },
    {
      "nct_id": "NCT00505934",
      "title": "Open-label Study of Levetiracetam Intravenous Infusion in Children (1 Month-4 Years Old) With Epilepsy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Epilepsy"
      ],
      "interventions": [
        {
          "name": "Levetiracetam",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "UCB Pharma SA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Month",
        "maximum_age": "4 Years",
        "sex": "ALL",
        "summary": "1 Month to 4 Years"
      },
      "enrollment_count": 19,
      "start_date": "2008-05",
      "completion_date": "2010-03",
      "has_results": true,
      "last_update_posted_date": "2015-07-15",
      "last_synced_at": "2026-10-02T05:48:06.315Z",
      "location_count": 6,
      "location_summary": "San Diego, California • Buffalo, New York • Philadelphia, Pennsylvania + 3 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Buffalo",
          "state": "New York"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Fort Worth",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00505934"
    },
    {
      "nct_id": "NCT01500278",
      "title": "Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "Certolizumab Pegol (CZP)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Adalimumab (ADA)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Methotrexate (MTX)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "UCB Pharma SA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 915,
      "start_date": "2011-12",
      "completion_date": "2016-01",
      "has_results": true,
      "last_update_posted_date": "2018-07-31",
      "last_synced_at": "2026-10-02T05:48:06.315Z",
      "location_count": 62,
      "location_summary": "Birmingham, Alabama • Tuscaloosa, Alabama • Tucson, Arizona + 56 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tuscaloosa",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        },
        {
          "city": "Covina",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01500278"
    },
    {
      "nct_id": "NCT01364597",
      "title": "Open-label Long-term Study of Adjunctive Brivaracetam in Pediatric Subjects With Epilepsy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Epilepsy"
      ],
      "interventions": [
        {
          "name": "Brivaracetam (BRV)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "UCB Pharma SA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "28 Days",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "28 Days to 17 Years"
      },
      "enrollment_count": 257,
      "start_date": "2011-08-01",
      "completion_date": "2022-02-03",
      "has_results": true,
      "last_update_posted_date": "2025-10-20",
      "last_synced_at": "2026-10-02T05:48:06.315Z",
      "location_count": 15,
      "location_summary": "Los Angeles, California • Gulf Breeze, Florida • Wellington, Florida + 12 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Gulf Breeze",
          "state": "Florida"
        },
        {
          "city": "Wellington",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01364597"
    },
    {
      "nct_id": "NCT01519791",
      "title": "A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "Certolizumab Pegol",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Methotrexate",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "UCB Pharma SA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 880,
      "start_date": "2012-01",
      "completion_date": "2015-09",
      "has_results": true,
      "last_update_posted_date": "2026-08-25",
      "last_synced_at": "2026-10-02T05:48:06.315Z",
      "location_count": 70,
      "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 63 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Paradise Valley",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01519791"
    },
    {
      "nct_id": "NCT00160706",
      "title": "A follow-on Safety Study in Subjects With Crohn's Disease Who Have Previously Been Withdrawn From the Double-blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425] Due to an Exacerbation of Crohn's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Crohn's Disease"
      ],
      "interventions": [
        {
          "name": "Certolizumab Pegol (CDP870)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "UCB Pharma SA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 310,
      "start_date": "2004-02",
      "completion_date": "2012-05",
      "has_results": true,
      "last_update_posted_date": "2018-08-07",
      "last_synced_at": "2026-10-02T05:48:06.315Z",
      "location_count": 41,
      "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Little Rock, Arkansas + 37 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00160706"
    },
    {
      "nct_id": "NCT00152503",
      "title": "Study With Subjects 18-65 Years Old With Partial Onset Seizures Who Are Currently Taking Levetiracetam",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Epilepsy, Partial"
      ],
      "interventions": [
        {
          "name": "Seletracetam (UCB44212)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "UCB Pharma SA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 59,
      "start_date": "2005-08-31",
      "completion_date": "2006-05-12",
      "has_results": true,
      "last_update_posted_date": "2023-09-07",
      "last_synced_at": "2026-10-02T05:48:06.315Z",
      "location_count": 14,
      "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • St. Petersburg, Florida + 11 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "St. Petersburg",
          "state": "Florida"
        },
        {
          "city": "Springfield",
          "state": "Illinois"
        },
        {
          "city": "Wichita",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00152503"
    }
  ]
}